|  |
| --- |
| [GSE3325](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE3325)  GSE197609 |
| GSE2443 |
| [**GSE221961**](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE221961) (beware of the methylation sequence)  Series GSE3325  GSE2443  GSE262940  GSE111177 (good one, high impact and low impact post ADT)  GSE80609 (RNAseq, only CaP and CPRC)  GSE35988  GSE104786  GSE67980  GSE32269  GSE32982  GSE37199  GSE28680  GSE5803 (depnedent and independent)  GSE28403 (CRPC vs LN pca)  GSE5377  GSE6811 |
|  |

**GSE3325**

A screenshot of a computer

AI-generated content may be incorrect.

**GSE2443**

**GSE221961**

A screenshot of a computer

AI-generated content may be incorrect.

1. Tumor cell-based liquid biopsy using high-throughput microfluidic enrichment of entire leukapheresis product - GSE255889 **(excluded)**
2. Prognostic implication of blood immune cell composition in Metastatic Castration-Resistant Prostate Cancer (mCRPC) - GSE248619 **(excluded)**
3. Genomic changes of Peripheral Blood Neutrophils throughout Prostate Cancer Progression - GSE197609
4. A landscape of circular RNAs expression in the castration-resistant prostate cancer - GSE125256 **(no control)**
5. Global Gene Expression Characterization of Circulating Tumor Cells in Metastatic Castration-Resistant Prostate Cancer Patients - GSE153514 **(no control)**
6. Molecular profiling of peripheral blood is associated with circulating tumor cells content and poor survival in metastatic castration-resistant prostate cancer - GSE66532 **(excluded)**
7. Gene expression profiles of PBMC in CRPC patients receiving persornalized peptide vaccination - GSE53922 **(excluded)**
8. Dysregulated expression of genes in regulatory T cells from metastatic castration-resistant prostate cancer patients - GSE38043 **(excluded)**